7 results on '"Hinojosa, Juan-Carlos"'
Search Results
2. Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender Women in the Global iPrEx Study
- Author
-
Liu, Albert, Glidden, David V, Anderson, Peter L, Amico, K Rivet, McMahan, Vanessa, Mehrotra, Megha, Lama, Javier R, MacRae, John, Hinojosa, Juan Carlos, Montoya, Orlando, Veloso, Valdilea G, Schechter, Mauro, Kallas, Esper G, Chariyalerstak, Suwat, Bekker, Linda-Gail, Mayer, Kenneth, Buchbinder, Susan, and Grant, Robert
- Subjects
Public Health ,Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Behavioral and Social Science ,Clinical Trials and Supportive Activities ,Sexual and Gender Minorities (SGM/LGBT*) ,Clinical Research ,Infectious Diseases ,Health Disparities ,6.1 Pharmaceuticals ,3.1 Primary prevention interventions to modify behaviours or promote wellbeing ,Infection ,Adolescent ,Adult ,Anti-Retroviral Agents ,Blood Chemical Analysis ,Chemoprevention ,Disease Transmission ,Infectious ,Drug Utilization ,Female ,HIV Infections ,Homosexuality ,Male ,Humans ,Male ,Medication Adherence ,Middle Aged ,Pre-Exposure Prophylaxis ,Transgender Persons ,United States ,Young Adult ,pre-exposure prophylaxis ,drug detection ,emtricitabine/tenofovir ,adherence ,men who have sex with men ,iPrEx Study team ,Public Health and Health Services ,Virology ,Clinical sciences ,Epidemiology ,Public health - Abstract
BackgroundAdherence to pre-exposure prophylaxis (PrEP) is critical for efficacy. Antiretroviral concentrations are an objective measure of PrEP use and correlate with efficacy. Understanding patterns and correlates of drug detection can identify populations at risk for nonadherence and inform design of PrEP adherence interventions.MethodsBlood antiretroviral concentrations were assessed among active arm participants in iPrEx, a randomized placebo-controlled trial of emtricitabine/tenofovir in men who have sex with men and transgender women in 6 countries. We evaluated rates and correlates of drug detection among a random sample of 470 participants at week 8 and a longitudinal cohort of 303 participants through 72 weeks of follow-up.ResultsOverall, 55% of participants (95% confidence interval: 49 to 60) tested at week 8 had drug detected. Drug detection was associated with older age and varied by study site. In longitudinal analysis, 31% never had drug detected, 30% always had drug detected, and 39% had an inconsistent pattern. Overall detection rates declined over time. Drug detection at some or all visits was associated with older age, indices of sexual risk, including condomless receptive anal sex, and responding "don't know" to a question about belief of PrEP efficacy (0-10 scale).ConclusionsDistinct patterns of study product use were identified, with a significant proportion demonstrating no drug detection at any visit. Research literacy may explain greater drug detection among populations having greater research experience, such as older men who have sex with men in the United States. Greater drug detection among those reporting highest risk sexual practices is expected to increase the impact and cost-effectiveness of PrEP.
- Published
- 2014
3. Los bonos verdes: el caso de Iberdrola
- Author
-
Fernández Hinojosa, Juan Carlos, Palacín Sánchez, María José, and Universidad de Sevilla. Departamento de Economía Financiera y Dirección de Operaciones
- Subjects
Bonos verdes ,Finanzas verdes ,Medio ambiente ,Iberdrola ,Sostenibilidad - Abstract
El presente trabajo profundiza en un instrumento financiero relativamente nuevo, los bonos verdes. Los bonos verdes son utilizados para financiar inversiones y proyectos comprometidos con el medio ambiente; el Acuerdo de París en 2015 supuso el impulso de este instrumento en los mercados financieros, y en los últimos años ha experimentado un enorme incremento tanto de emisores como de volúmenes de emisión. En la primera parte de este trabajo, se pretende conocer el funcionamiento, regulación, y evolución de los bonos verdes desde sus inicios en 2007. En la segunda parte de este trabajo, se pretende estudiar el caso particular de la empresa española con mayor importancia en el mercado de bonos verdes, Iberdrola, y se realiza un análisis de todos los bonos verdes emitidos por esta empresa para terminar comparando estos bonos con los bonos convencionales emitidos por la misma Universidad de Sevilla. Grado en Finanzas y Contabilidad
- Published
- 2018
4. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
- Author
-
Llanos-Cuentas, Alejandro, Casapia, Martin, Chuquiyauri, Raúl, Hinojosa, Juan-Carlos, Kerr, Nicola, Rosario, Maria, Toovey, Stephen, Arch, Robert H, Phillips, Margaret A, Rozenberg, Felix D, Bath, Jade, Ng, Caroline L, Cowell, Annie N, Winzeler, Elizabeth A, Fidock, David A, Baker, Mark, Möhrle, Jörg J, Hooft van Huijsduijnen, Rob, Gobeau, Nathalie, Araeipour, Nada, Andenmatten, Nicole, Rückle, Thomas, and Duparc, Stephan
- Subjects
Oxidoreductases Acting on CH-CH Group Donors ,Plasmodium falciparum ,Dihydroorotate Dehydrogenase ,DSM265 ,Triazoles ,purl.org/pe-repo/ocde/ford#3.03.08 [https] ,Article ,Antimalarial activity ,Antimalarials ,novel plasmodium dihydroorotate dehydrogenase inhibitor ,Pyrimidines ,malaria infection ,parasitic diseases ,Malaria, Vivax ,Humans ,Malaria, Falciparum ,Plasmodium vivax - Abstract
Summary Background DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum. This study aimed to assess the efficacy of DSM265 in patients with P falciparum or Plasmodium vivax malaria infection. Methods This proof-of-concept, open-label, phase 2a study was conducted at the Asociación Civil Selva Amazónica in Iquitos, Peru. Patients aged 18–70 years, weighing 45–90 kg, who had clinical malaria (P falciparum or P vivax monoinfection) and fever within the previous 24 h were eligible. Exclusion criteria were clinical or laboratory signs of severe malaria, inability to take oral medicine, and use of other antimalarial treatment in the preceding 14 days. Patients were divided into cohorts of those with P falciparum (cohort a) or P vivax (cohort b) infection. Two initial cohorts received single oral doses of 400 mg DSM265. Patients were followed up for efficacy for 28 days and safety for 35 days. Further cohorts received escalated or de-escalated doses of DSM265, after safety and efficacy assessment of the initial dose. The primary endpoints were the proportion of patients achieving PCR-adjusted adequate clinical and parasitological response (ACPR) by day 14 for patients infected with P falciparum and the proportion of patients achieving a crude cure by day 14 for those infected with P vivax. Cohort success, the criteria for dose escalation, was defined as ACPR (P falciparum) or crude cure (P vivax) in at least 80% of patients in the cohort. The primary analysis was done in the intention-to-treat population (ITT) and the per-protocol population, and safety analyses were done in all patients who received the study drug. This study is registered at ClinicalTrials.gov (NCT02123290). Findings Between Jan 12, 2015, and Dec 2, 2015, 45 Peruvian patients (24 with P falciparum [cohort a] and 21 with P vivax [cohort b] infection) were sequentially enrolled. For patients with P falciparum malaria in the per-protocol population, all 11 (100%) in the 400 mg group and eight (80%) of ten in the 250 mg group achieved ACPR on day 14. In the ITT analysis, 11 (85%) of 13 in the 400 mg group and eight (73%) of 11 in the 250 mg group achieved ACPR at day 14. For the patients with P vivax malaria, the primary endpoint was not met. In the per-protocol analysis, none of four patients who had 400 mg, three (50%) of six who had 600 mg, and one (25%) of four who had 800 mg DSM265 achieved crude cure at day 14. In the ITT analysis, none of five in the 400 mg group, three (33%) of nine in the 600 mg group, and one (14%) of seven in the 800 mg group achieved crude cure at day 14. During the 28-day extended observation of P falciparum patients, a resistance-associated mutation in the gene encoding the DSM265 target DHODH was observed in two of four recurring patients. DSM265 was well tolerated. The most common adverse events were pyrexia (20 [44%] of 45) and headache (18 [40%] of 45), which are both common symptoms of malaria, and no patients had any treatment-related serious adverse events or adverse events leading to study discontinuation. Interpretation After a single dose of DSM265, P falciparum parasitaemia was rapidly cleared, whereas against P vivax, DSM265 showed less effective clearance kinetics. Its long duration of action provides the potential to prevent recurrence of P falciparum after treatment with a single dose, which should be further assessed in future combination studies. Funding The Global Health Innovative Technology Fund, the Bill & Melinda Gates Foundation, the National Institutes of Health (R01 AI103058), the Wellcome Trust, and the UK Department of International Development.
- Published
- 2018
5. Identificación de ciclos financieros en tiempo real para el IPC mediante la red neuronal artificial LVQ
- Author
-
Torre Hinojosa, Juan Carlos de la and Hernández Álvarez, Federico
- Subjects
Ciencias Físico-Matemáticas e Ingenierías - Abstract
Ingeniería
- Published
- 2016
6. REPORT OF AN UNUSUAL CASE OF PERSISTENT BACTEREMIA BY BARTONELLA BACILLIFORMIS IN A SPLENECTOMIZED PATIENT
- Author
-
HENRÍQUEZ, CÉSAR, primary, MERELLO, JENNY, additional, MAGUIÑA, CIRO, additional, HINOJOSA, JUAN CARLOS, additional, VENTOSILLA, PALMIRA, additional, MALLQUI, VANIA, additional, VERASTEGUI, MANUELA, additional, and INFANTE, BERONICA, additional
- Published
- 2004
- Full Text
- View/download PDF
7. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study.
- Author
-
Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M, Lama JR, MacRae J, Hinojosa JC, Montoya O, Veloso VG, Schechter M, Kallas EG, Chariyalerstak S, Bekker LG, Mayer K, Buchbinder S, and Grant R
- Subjects
- Adolescent, Adult, Anti-Retroviral Agents analysis, Blood Chemical Analysis, Drug Utilization, Female, Humans, Male, Medication Adherence, Middle Aged, United States, Young Adult, Anti-Retroviral Agents therapeutic use, Chemoprevention statistics & numerical data, Disease Transmission, Infectious prevention & control, HIV Infections prevention & control, Homosexuality, Male, Pre-Exposure Prophylaxis statistics & numerical data, Transgender Persons
- Abstract
Background: Adherence to pre-exposure prophylaxis (PrEP) is critical for efficacy. Antiretroviral concentrations are an objective measure of PrEP use and correlate with efficacy. Understanding patterns and correlates of drug detection can identify populations at risk for nonadherence and inform design of PrEP adherence interventions., Methods: Blood antiretroviral concentrations were assessed among active arm participants in iPrEx, a randomized placebo-controlled trial of emtricitabine/tenofovir in men who have sex with men and transgender women in 6 countries. We evaluated rates and correlates of drug detection among a random sample of 470 participants at week 8 and a longitudinal cohort of 303 participants through 72 weeks of follow-up., Results: Overall, 55% of participants (95% confidence interval: 49 to 60) tested at week 8 had drug detected. Drug detection was associated with older age and varied by study site. In longitudinal analysis, 31% never had drug detected, 30% always had drug detected, and 39% had an inconsistent pattern. Overall detection rates declined over time. Drug detection at some or all visits was associated with older age, indices of sexual risk, including condomless receptive anal sex, and responding "don't know" to a question about belief of PrEP efficacy (0-10 scale)., Conclusions: Distinct patterns of study product use were identified, with a significant proportion demonstrating no drug detection at any visit. Research literacy may explain greater drug detection among populations having greater research experience, such as older men who have sex with men in the United States. Greater drug detection among those reporting highest risk sexual practices is expected to increase the impact and cost-effectiveness of PrEP.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.